SLC39A6 CN gains were observed in 49/1980 (2.5%) of the entire cohort and 35/1471 (2.3%) of the ER + tumours, whereas 80/1980 (4.0%) of the entire cohort and 66/1440 (4.4%) of the ER + tumours exhibited CN loss, respectively. Here, SLC39A6 is linked to neoplasm.